News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

airPharma Adds Executives In Corporate & Product Development

10/19/2005 5:12:20 PM

OVERLAND PARK, Kan., Nov. 30 /PRNewswire/ -- airPharma, a specialty pharmaceutical company focused on commercializing products that address unmet needs in respiratory diseases, today announced it has added two experienced pharmaceutical executives to the company's management team. Peter T. Higuchi has joined airPharma as Vice President, Corporate Development, and Ed Mitchell, Ph.D., has joined as Vice President, Product Development.

"As airPharma moves from the startup stage to commercialization, we've assembled a team with the experience and drive to build a valuable pipeline of drugs for respiratory diseases. We are very pleased to announce the hiring of Ed Mitchell and Peter Higuchi, seasoned experts who can carry airPharma forward in our drug development and strategic alliances," said Doug Dockhorn, President and Chief Executive Officer of airPharma.

Mr. Higuchi is spearheading product licensing and strategic alliances for airPharma, bringing more than 20 years of experience in related fields. Previously, he was president and Chief Executive Officer of CyDex, Inc., a specialty pharmaceutical company focused on applications of drug delivery technology. Mr. Higuchi founded CyDex in 1993, built a team of scientists and staff, and forged numerous corporate alliances to create a pipeline of pharmaceutical products. Mr. Higuchi also has served as a member of the Board of Directors of various pharmaceutical organizations.

In previous ventures, Mr. Higuchi consulted in corporate finance, technology transfer and business development as President of Higuchi & Co; worked in licensing and corporate development for Marion Laboratories and Marion Merrell Dow; and was a consultant with Touche Ross & Co. He holds a B.A. from the University of Kansas, a J.D. from Washburn University School of Law and an M.I.M. from the American Graduate School of International Management.

Dr. Mitchell leads airPharma's product development team, drawing on more than 30 years of drug development and regulatory management experience. Most recently, he was North American Head of Industrial Operations Chemistry Manufacturing and Controls (CMC) for Aventis Pharmaceuticals. Previously, Dr. Mitchell was Director of Product Development Services for PRA International, responsible for development strategy for several respiratory products. In prior positions, he served as Chief Regulatory Officer for Oread, Inc.; Vice President of U.S. Regulatory Affairs for IVAX Corporation; and a number of positions in drug development and regulatory affairs for Marion Laboratories and Marion Merrell Dow.

Dr. Mitchell's experience encompasses products in a broad range of therapeutic areas, including respiratory/pulmonary. He has interacted directly with the FDA as liaison for the approval and ongoing marketing of several products, including branded and generic drugs for respiratory and allergic diseases. Dr. Mitchell has been an author on numerous scientific publications and has served as an expert for FDA review of NDAs in the dental drug market. He received bachelor's degrees in Biology and Education from Kansas State University and a Ph.D. in Pharmacology and Physiology from the University of Missouri-Kansas City.

About airPharma

airPharma is a specialty pharmaceutical company focused on commercializing products that address unmet needs in respiratory diseases. The company is developing a portfolio of branded respiratory products. The company was founded in 2002 by Dr. Robert Dockhorn and Doug Dockhorn. Prior to airPharma, the Dockhorns built their previous company, IMTCI, into the leader in conducting respiratory clinical studies. airPharma is privately held and is located in Overland Park, KS. For further information, visit airPharma's website at .


CONTACT: Media, James A. Byrnes, Executive Vice President, GlobalCommercialization, of airPharma, +1-913-498-0700,

Read at

comments powered by Disqus